Amicus Therapeutics, Inc.

Amicus Therapeutics Beats on EPS, Stock Up 1.98%

Amicus Therapeutics reported a narrower-than-expected loss per share, which led to a positive stock reaction, with shares rising by nearly 2%. However, there was no revenue reported or guidance provided, leaving investors with limited insight into future performance. The surprise in EPS suggests some operational efficiency, but the lack of revenue details raises questions about overall business health.